Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Expected to Post Earnings of -$0.14 Per Share
Analysts expect Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) to announce earnings of ($0.14) per share for the current quarter, Zacks reports. Three analysts have provided estimates for Infinity Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.14) and the highest estimate coming in at ($0.13). Infinity Pharmaceuticals posted earnings of ($0.19) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 26.3%. The business is scheduled to report its next earnings results on Monday, May 10th.
According to Zacks, analysts expect that Infinity Pharmaceuticals will report full year earnings of ($0.55) per share for the current financial year, with EPS estimates ranging from ($0.62) to ($0.52). For the next financial year, analysts forecast that the firm will report earnings of ($0.57) per share, with EPS estimates ranging from ($0.66) to ($0.47). Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Infinity Pharmaceuticals.
Infinity Pharmaceuticals (NASDAQ:INFI) last issued its quarterly earnings results on Monday, March 15th. The biotechnology company reported ($0.16) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.16). Infinity Pharmaceuticals had a negative return on equity of 1,358.77% and a negative net margin of 2,592.65%.
In related news, major shareholder Bvf Partners L. P/Il sold 5,848,520 shares of the business’s stock in a transaction dated Friday, January 22nd. The stock was sold at an average price of $4.14, for a total transaction of $24,212,872.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 13.77% of the stock is currently owned by insiders.
Institutional investors have recently bought and sold shares of the stock. Renaissance Technologies LLC grew its position in Infinity Pharmaceuticals by 24.0% during the fourth quarter. Renaissance Technologies LLC now owns 2,215,974 shares of the biotechnology company’s stock worth $4,698,000 after buying an additional 429,041 shares in the last quarter. Morgan Stanley grew its position in Infinity Pharmaceuticals by 268.9% during the third quarter. Morgan Stanley now owns 35,251 shares of the biotechnology company’s stock worth $41,000 after buying an additional 25,695 shares in the last quarter. BlackRock Inc. grew its position in Infinity Pharmaceuticals by 0.6% during the fourth quarter. BlackRock Inc. now owns 976,446 shares of the biotechnology company’s stock worth $2,071,000 after buying an additional 5,748 shares in the last quarter. Callan Capital LLC purchased a new position in Infinity Pharmaceuticals during the fourth quarter worth about $155,000. Finally, JPMorgan Chase & Co. grew its position in Infinity Pharmaceuticals by 165,024.0% during the fourth quarter. JPMorgan Chase & Co. now owns 41,281 shares of the biotechnology company’s stock worth $88,000 after buying an additional 41,256 shares in the last quarter. Institutional investors and hedge funds own 46.66% of the company’s stock.
Infinity Pharmaceuticals stock traded up $0.17 during mid-day trading on Friday, reaching $3.51. 35,600 shares of the company’s stock were exchanged, compared to its average volume of 3,897,280. The business’s fifty day simple moving average is $3.27 and its 200 day simple moving average is $2.43. Infinity Pharmaceuticals has a one year low of $0.78 and a one year high of $5.98. The firm has a market capitalization of $311.13 million, a PE ratio of -4.70 and a beta of 2.40.
About Infinity Pharmaceuticals
Infinity Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing novel medicines for people with cancer. It offers IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the enzyme phosphoinositide-3-kinase-gamma Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study.
Read More: What is channel trading?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Infinity Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.